Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Assessment of the Symptomatic Burden of Patients With Advanced Chronic Liver Disease. Correlation Between the Model for End-Stage Liver Disease (MELD)-Na and the Edmonton Symptom Assessment System Scale (ESAS).

NCT06181474 is registered in ClinicalTrials.gov with Unidade Local de Saúde de Matosinhos, EPE as lead sponsor.

NCT NCT06181474
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06181474 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Assessment of the Symptomatic Burden of Patients With Advanced Chronic Liver Disease. Correlation Between the Model for End-Stage Liver Disease (MELD)-Na and the Edmonton Symptom Assessment System Scale (ESAS).
Lead sponsor
Unidade Local de Saúde de Matosinhos, EPE
Phase
Observational
Overall status
Completed
Start date
January 1, 2024
Completion date
January 25, 2025
Enrollment
44 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

end stage liver disease, palliative care